Nurse-Provided Education Crucial to Sural Nerve Graft Prostatectomy Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

SAN DIEGO--Sural nerve grafting is a new procedure that may allow prostate patients undergoing radical prostatectomy to maintain sexual potency. With limited information currently available about the procedure, the ambulatory nurse’s role in educating these patients can be critical in alleviating anxiety and stress, said Mary Schoen, RN, MSN, MPH, a clinical nurse in Memorial Sloan-Kettering Cancer Center’s Urology Department.

SAN DIEGO--Sural nerve grafting is a new procedure that may allow prostate patients undergoing radical prostatectomy to maintain sexual potency. With limited information currently available about the procedure, the ambulatory nurse’s role in educating these patients can be critical in alleviating anxiety and stress, said Mary Schoen, RN, MSN, MPH, a clinical nurse in Memorial Sloan-Kettering Cancer Center’s Urology Department.

Ms. Schoen and her colleague, Dominique DePalma, RN, MA, OCN, also a clinical nurse in the Urology Department, discussed the importance of providing support and education to this population at the 26th Annual Conference of the Oncology Nursing Society (abstract 72).

If tumor invasion into the neurovascular bundle branches is detected during surgery, the nerves allowing erectile function must be resected.

"For men unable to have nerve-sparing surgery, the surgeon will perform a sural nerve graft, taking a nerve from around the ankle bone and placing it around the prostate," Ms. Schoen said. Sural nerve graft patients are expected to regain erectile function within 14 to 18 months after the surgery.

Patients are extremely nervous prior to the surgery and even after surgery, the nurses said. "We get a lot of phone calls. They need a great deal of support," Ms. Schoen said. "Our job is to provide patient education, do referrals to erectile dysfunction specialists, start them on Viagra, and just reassure them." Ms. DePalma noted that the men who have the surgery have more advanced cancer than other patients, so they may need more education and support.

Said Ms. Schoen: "We’re educating other nurses about this new procedure so that they, in turn, can help alleviate patient concerns and make the appropriate referrals." 

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content